Carcinoma Oesophagus - A Re-evaluation of Risk factors, Clinical features and Management. by Chitra, S
CARCINOMA  OESOPHAGUS
A RE-EVALUATION OF RISK 
FACTORS, CLINICAL FEATURES & 
MANAGEMENT 








            A RE-EVALUATION
                       OF 
RISK FACTORS, CLINICAL
  FEATURES & MANAGEMENT
              
               CERTIFICATE
                    This is to certify that this dissertation entitled “Carcinoma 
oesophagus-  A  re-evaluation  of  risk  factors,  clinical  features  & 
management”  submitted  by  Dr.S.Chitra,  to  the  faculty  of  Medical 
Gastroenterology, The Tamilnadu Dr.MGR Medical University, Guindy, 
Chennai-600032, in partial fulfillment of the requirement for the award 
of  DM.,  Degree  Branch  IV  (  Gastroenterology)  is  a  bonafide  work 
carried out by her under my direct supervision and guidance. 
Prof.S.Jeevan Kumar,MD.,DM.,                     
                    (Gastroenterology)
Professor and HOD, 
Department of Digestive Health and Diseases,
Government Peripheral Hospital, Anna Nagar, 
Attached to Kilpauk Medical College,
Chennai-600010




Government Kilpauk Medical 
College, Kilpauk, Chennai-600010
               ACKNOWLEDGEMENT
         At the outset, I wish to express my thanks to our Dean 
Dr.M.Dhanapal,MD.,DM(Cardiology)., Government  Kilpauk  Medical  College, 
Kilpauk, Chennai-600010 and Dr.M.Anand Babu, MS., Former Civil Surgeon Medical 
Officer, Government Peripheral Hospital, Anna Nagar,Chennai-600102, for permitting 
me to utilize the clinical materials from this hospital.
               I wish to express my sincere thanks and gratitude to my Professor, 
Dr.S.JeevanKumar,MD.,DM., Head  of  the  Department,  Department  of  Digestive 
Health and Diseases& Civil Surgeon Medical Officer, Government Peripheral Hospital , 
Anna Nagar, attached to Kilpauk Medical College, Chennai-600010, for his meticulous 
guidance and constant encouragement throughout the study.
              I  express  my  extreme  gratitude  to  my  Additional  Professor, 
Dr.T.Pugazhendhi, MD.,DM.,for offering me timely advice and help.
              I am extremely thankful to Dr.Mohammed Ali, MD., DM., for his 
consistent support and  guidance during his stay with us. I am extremely grateful to 
Dr.A.R.Venkateswaran,  MD.,  DM,  and  Dr.R.Balamurali,  MD.,  DM.,  & 
Dr.P.Nageshwara Rao, MD., DM., for their help and eminent guidance throughout the 
study.
         I  am thankful  to all  the  faculties  of  the Departments  in  Government 
Peripheral Hospital in general and Radiology Department in particular for their kind co-
operation throughout the study.
         I extend my sincere gratitude to  Prof. Vijayalakshmi, MD., Professor of 
Pathology and her team for their support  in getting the  histopathological report quickly.
                     I  express  my  special thanks to Dr.P.Manickam, Scientist. ICMR,  for his  
help in doing the statistical analysis.
It  is  a  special  pleasure  to  acknowledge  the  help  of  staff  nurses  and 
endoscopy assistants for their deep commitments to the work.
          I owe special thanks to my post-graduate colleagues Dr.S.Arulprakash, 
Dr.P.Ratnakar  Kini,  Dr.Manimaran,  Dr.Rajan  Babu,  Dr.  Senthil  Kumaran,  & 
Dr.Shameem Ahmed, for their support and encouragement.
           I thank all the referring Institutions and doctors for their trust and timely 
referral  of  needy  patients  to  our  department.  I  thank  all  the  patients  who  have 
ungrudgingly lent themselves to undergo this study without which this study would not 
have seen the light of the day. 
TABLE OF CONTENTS
Sl. No. TITLE                                PAGE No.
1) INTRODUCTION                                      1     
2) LITERATURE REVIEW                                      3   
3) AIM OF THE STUDY                                    43  
4) MATERIALS AND METHODS                            44
5) RESULTS                                                       46
6) DISCUSSION                                             56
7) CONCLUSION                                                       64
8) BIBLIOGRAPHY                                
INTRODUCTION
                        Oesophageal cancer is a common malignancy with a very poor  
prognosis. It is the sixth  most common fatal cancer in the world, causing over 300,000  
deaths each year1.  The five   year relative survival rate in U.S.A was 14%, among the  
lowest for all cancer2. The main  reason for this poor prognosis is that most cases are 
asymptomatic and  go undetected until they  have  spread  beyond  the  esophagus  and  
are  unresectable.
                        Using  a  age  standarised  rate,  incidence  is  estimated  worldwide  at  
11.5/100,000 in  men  and  4.7/100,000  in  women. Much  higher  rates  occur  in  
certain  regions  of  Asia, such  as  Cixian  in  China  and  of  Africa3.  While in most  
part of the world, the incidence is approximately 5/100,000 population, it may exceed  
100/100,000 in countries like India & other Asian countries4.                                 
                             Among  the  digestive  tract  cancers  in  India,  esophagus  is  the  
commonest  site  in  both  men  and  women.5 It  is  the  third  leading  cause  of  death 
in  men  and  fourth  leading  cause  in  women. Lowest  incidence  has  been  reported  
from  Punjab.6
                                         At  initial  presentation,  50-60% of  patients  have  a  non  resectable  
tumour. Surgical  resection  has  long  been  considered  to  be  the  only  curative  
treatment in  the  absence  of  distant  metastasis  or  local  lymph  node  metastases.  
However  even  after  an  optimal  resection,  which  is  feasible  only  in  approximately  
10%  of  cases,  the  overall  survival  rate  ranges  between 20% and  50% according 
to  stage7.
                           The  importance  of  diet  and  nutrition  in  the  etiology  of  many 
cancers  has  gained   wide  acceptance. Nutritional  factors  directly  or  indirectly   has 
also    been  implicated  in  cancer  oesophagus. In  high  incidence  areas  like  Iran, 
where  people    neither  smoke  nor  drink,  lack  of  fresh  fruits  and  vegetables, 
deficiency  of  vitamin A,  riboflavin  has  resulted  in mucosal  damage8. Limited  data 
are  available  from  our  country  regarding  risk  factors  analysis  and  presentation  of 
cancer  oesophagus. Hence the  present  study  was   undertaken  to  study  about  the 
risk  factors,  presentations,  and  treatment  modalities  of  oesophageal  cancer.
                                    
REVIEW  OF  LITERATURE
                         Cancer of the oesophagus remains a devastating disease because it is  
usually not detected until it has progressed to an advanced incurable stage. Worldwide, 
oesophageal cancer is the sixth leading cause of death from cancer. The lifetime risk of 
this  cancer  is  0.8%  for  men  and  0.3%  for  women9. Modern  imaging  techniques, 
including  contrast-enhanced  computed  tomography,  magnetic  resonance  imaging, 
endoscopic ultrasonography, and positron-emission tomography   are powerful tools in 
the detection, diagnosis,  and staging of this malignancy. Early detection remains the 
elusive but essential goal of research. Only surgical resection at a very early stage has 
been shown to improve survival rates in patients with this disease.
                           Cancer of the oesophagus accounts for 7% of  the gastrointestinal tract 
cancers in the United States. In the past, squamous cell carcinoma accounted for more 
than 95% of cases of oesophageal cancer. However, by the early 1990s, adenocarcinoma 
had become the most common cancerous cell type among white Americans, accounting 
for  approximately  one  half  of  oesophageal  malignancies  in  the  United  States  and 
Europe. Squamous cell cancers still predominate among African American patients.
                        Worldwide, certain geographic regions have a high incidence of 
oesophageal squamous cell carcinoma. There exists  a  very  high  incidence  area  called 
“ oesophageal  cancer  belt” stretching  from  the region of the Caspian Sea eastward 
through Central Asia to northern China10.
                       The incidence is 7.4/100,000 in UK, 87/100,000 in Japan and 100/100,000 
in Asian countries11. In India the lowest incidence has been reported from Chandigarh 
3.5/1,00,000 and highest  from Dibugarh 19.7/1,00,000.Extremely high incidence rates, 
reaching endemic proportions have been reported from Jammu & Kashmir which seems 
to fall in the Asian oesophageal cancer belt. The unique personal and dietary habits  and 
environmental factors in Kashmir have been attributed to the high risk4.According to 
Chennai cancer registry, cancer esophagus ranks the third common malignancy in males 
and fourth common malignancy in females12.
ANATOMY
                   The oesophagus is a muscular tube extending from the pharynx to the 
stomach. Histologically, the oesophageal wall contains 4 major layers: 
• Mucosa or a mucous membrane composed of the lining epithelium; the lamina 
propria,  a  layer  of  loose  connective  tissue  enriched  with  capillaries  and 
lymphatics; and the muscularis mucosae, a thin double layer of smooth muscle
• Submucosa, a loose connective tissue layer also rich in capillaries and lymphatics
• Muscularis  externa (propria),  consisting of  2  layers  of  muscle,  the inner layer 
deployed circumferentially, and the outer layer arranged longitudinally
• Loose adventitia (unlike other areas of the gastrointestinal tract, which have a true 
serosa)
Because the oesophagus lacks a serosal  covering,  oesophageal  carcinoma encounters 
few anatomic barriers to local invasion.
                          The cervical oesophagus is that portion extending from the inferior 
aspect  of  the cricoid cartilage to  the thoracic  inlet.  Caudal  to  the thoracic  inlet,  the 
thoracic oesophagus is divided into thirds: The upper third extends from the thoracic 
inlet to the carina, and the middle and lower thirds are defined as the cranial and caudal 
halves of the remaining oesophagus from the carina to the gastroesophageal junction.
                            The oesophagus is drained by a rich network of lymphatics; therefore, 
precisely determining the particular draining lymph node chain for a given segment is 
often difficult. Jump lymph-node metastases occur when a node close to the involved 
oesophageal  segment  is  not  diseased,  but  a  more  distant  node  is  diseased.  For  the 
cervical oesophagus, cervical and supraclavicular lymph nodes are considered local, and 
mediastinal and upper abdominal lymph nodes are considered distant. For the upper and 
mid thoracic oesophagus, mediastinal lymph nodes are considered local, and involved 
cervical,  supraclavicular,  and abdominal lymph nodes are considered distant.  For the 
lower  oesophagus,  mediastinal  and  perigastric  lymph  nodes  are  considered  local, 
whereas  involved  cervical,  supraclavicular,  and  celiac  lymph  nodes  are  considered 
distant.
PATHOPHYSIOLOGY
                           The most common types of oesophageal carcinoma are squamous cell  
carcinoma and adenocarcinoma. 
SQUAMOUS CELL CARCINOMA
                            The normal oesophagus is lined by stratified squamous nonkeratinizing 
epithelium.  Alcohol  and  tobacco  use  are  the  principal  modifiable  risk  factors  for 
oesophageal squamous cell carcinoma. According to the American Cancer Society, the 
combination of long-term alcohol ingestion and tobacco use is the most substantial risk 
factor.  Nitrosamines  and  other  nitrosyl  compounds  are  found  in  pickled  vegetables, 
smoked meat, and the water supply of certain geographic regions where the incidence of 
oesophageal squamous cell carcinoma is high. In regions in which the soil is deficient in 
molybdenum and  zinc,  plants  are  impaired  in  their  ability  to  metabolize  nitrites  to 
ammonia. This impairment permits potentially toxic nitrogen compounds to accumulate 
within plants that enter the human food supply.
                             Anecdotal associations have been made between oesophageal 
squamous cell carcinoma and chronic consumption of hot liquids, betel nuts, asbestos, 
air pollution, and diets high in spice content. Conversely, consumption of a diet high in 
fruits and vegetables has a protective effect.
                           Certain medical conditions predispose patients to the development of 
oesophageal squamous cell carcinoma. These include achalasia, lye strictures, head and 
neck tumors, celiac disease, Plummer-Vinson syndrome, tylosis, and prior exposure to 
radiation. Squamous cell carcinoma may arise in the setting of achalasia, typically after 
a period of 20 or more years, and it is believed to result from long-standing irritation by 
retained  material.  Of  patients  with  strictures  caused  by  lye  ingestion,  3%  develop 
squamous cell carcinomas after 20-40 years. The association of head and neck tumors 
with squamous cell carcinoma of the oesophagus is explained best by the common risk 
factors of alcohol and tobacco use.
                            Plummer-Vinson syndrome consists of dysphagia, iron-deficiency  
anemia, and oesophageal webs. Patients with this syndrome have an increased incidence 
of postcricoid squamous cell carcinoma. Squamous cell carcinoma of the oesophagus 
occurs  in  almost  all  patients  with  tylosis,  a  rare  autosomal  dominant  disorder 
characterized by esophageal papillomas and hyperkeratosis of the palms and soles.
                           Infection with human papillomavirus, particularly subtypes 16 and 18, 
has been implicated in the pathogenesis of oesophageal squamous cell carcinoma.
ADENOCARCINOMA
                            Adenocarcinoma, which is most common in the mid and distal  
oesophagus,  arises  from  abnormal  oesophageal  mucosa  in  a  well-characterized 
sequence.  In  reaction  to  chronic  gastroesophageal  reflux,  metaplasia  of  the  normal 
stratified squamous epithelium of the distal oesophagus occurs, resulting in a specialized 
intestinal glandular epithelium containing goblet cells called Barrett epithelium. Further 
genetic alterations in this epithelium lead to dysplasia, which may progress from low-
grade to high-grade dysplasia and, ultimately, to adenocarcinoma.
                           Gastroesophageal reflux disease (GERD) is the most important factor in 
the development of Barrett epithelium. Of patients with GERD, 10% develop Barrett 
epithelium.  Of  patients  with  Barrett  epithelium,  1%  develop  oesophageal 
adenocarcinoma, a risk that is 30-40 times higher than in the population without Barrett 
epithelium.
                             Smoking has been identified as a risk factor. Scleroderma and other 
motor disorders of the oesophagus that predispose patients to GERD increase the risk 
accordingly. Obesity, certain medications, environmental exposures,  diet and nutritional 
habits have been implicated as additional risk factors.
RACE
                          African Americans are 3 times more likely than whites to develop 
cancer  of  the  oesophagus.  Although  squamous  cell  carcinoma  is  relatively  more 
common in African Americans, adenocarcinoma is more common in white Americans.
SEX
                          Males are 3 times more likely to develop oesophageal carcinoma than 
females.
AGE
                    Incidence of both squamous cell carcinoma and adenocarcinoma increases 
with age.
PROGNOSIS
                           Only early surgical resection improves survival rates in patients with 
this disease. Of patients with oesophageal cancer, 50% present with metastatic disease 
and most  patients  with apparent  local  disease  develop metastases despite  potentially 
curative local therapy. The primary cause of death in patients who are treated surgically 
is local recurrence, compared to other gastrointestinal tract tumors in which metastatic 
disease is usually the cause. 
                           Prognosis depends on depth of tumor penetration through the  
oesophageal wall and the presence of lymph node metastases. The TNM system is used 
to classify the extent of disease.
                                Metastatic disease from a primary lesion in the lower oesophagus is 
classified  as  M1a  if  celiac  nodes  are  involved.  M1b  designates  metastatic  disease 
beyond  locoregional  and  celiac  lymph  nodes.  For  a  primary  lesion  in  the  mid 
oesophagus, the M1a status is not applicable; metastatic disease beyond locoregional 
lymph  nodes  is  designated  M1b.  For  a  primary  lesion  in  the  upper  oesophagus, 
involvement  of  cervical  lymph  nodes  is  designated  M1a;  metastatic  disease  beyond 
locoregional and cervical lymph nodes is designated M1b.
                           Staging groups are formed on the basis of the TNM classifications and 
are used to guide therapy and predict the prognosis and survival.
                                        Staging of Oesophageal Carcinoma
Stage TNM 5-Year Survival Rate
0 Tis, NO, MO 75%
I T1, NO, MO 50%
IIA T2, NO, MO or T3, NO, MO 40%
IIB T1, N1, MO or T2, N1, MO 20%
III T3, N1, MO or T4, any N, MO 15%
IVA Any T, any N, M1a <1%
IVB Any T, any N, M1b <1%
CLINICAL FEATURES
                         SCC occurs predominantly in the middle and upper thirds of the 
oesophagus, while AdenoCA occurs predominantly in the distal third of the oesophagus 
and at the EG junction. Dysphagia is the most common symptom (90%), followed by 
odynophagia (50%). The presence of odynophagia coincides with an ulcerated tumor. 
Up  to  75% of  patients  have  experienced  anorexia  and  weight  loss  when  they  seek 
medical  attention.  Chest  pain  or  pain  radiating  to  the  back  is  a  particularly  sinister 
symptom, in that it implies invasion into neuromediastinal structures.
                                 Advanced lesions typically appear exophytic as polypoid,  
fungating, or ulcerated masses. Lesions may be eccentric or circumferential. SCC of the 
oesophagus  is  an  aggressively  invasive  tumor.  Vocal  cord  paralysis  accompanies 
recurrent laryngeal nerve invasion. Cough or recurrent pneumonia may indicate chronic 
aspiration as a result of oesophageal obstruction or oesophagorespiratory fistula due to 
direct  tumor  extension.  Oesophagorespiratory  fistulas  occur  in  5%  of  patients.  The 
development of an oesophagorespiratory fistula confers a particularly poor prognosis 
with a median survival time of 1.5 to 4 months. Pulmonary, hepatic, bone, and brain 
metastasis  may  all  be  observed  at  presentation  or  during  tumor  progression. 
Hematemesis may be due to tumor ulceration. Exsanguinating bleeds occur with the 
development of an aortoesophageal fistula.
                                      AdenoCAs are not similarly locally invasive. Lymphangitic and 
hematogenous metastases, however, do occur early to regional and distant lymph nodes 
and to the liver.  Tumors limited to the mucosa have lymph node metastases in only 
approximately 3% of cases.  However,  once the tumor has penetrated the muscularis 
mucosa and invaded the submucosa, lymph node metastases are documented in 30% of 
cases, and when into the muscularis propria, in 60% of cases. 
SCREENING 
                                Screening refers to the application of diagnostic testing in 
asymptomatic individuals to determine if they have a pathologic process or a precursor 
lesion. Surveillance refers to the application of diagnostic testing in individuals known 
to have had the defined pathology or its precursor lesion to determine if the lesion has 
progressed, regressed, or remained stable, or if it has been previously treated whether the 
initial lesion remains or if new lesions are present. Screening for oesophageal cancer 
may employ nonendoscopic and/or endoscopic technique. Surveillance generally uses 
endoscopy.  Cytologic and molecular techniques are the two non-endoscopic techniques 
that have been used with high-risk groups.
                                 In the balloon technique, a deflated balloon covered by a cloth net  
or rubber ribbing is swallowed into the stomach, inflated, and then withdrawn, collecting 
exfoliated  cells  and  scraping  the  mucosal  surface  of  the  oesophagus.  At  the  upper 
oesophageal sphincter, the balloon is deflated and removed. In the sponge technique, a 
polyurethane mesh is compressed inside a gelatin capsule and attached to a string or a 
thin  plastic  stylet.  The  capsule  is  swallowed  into  the  stomach,  where  the  gelatin 
dissolves, and the mesh expands. Then the mesh is pulled up the oesophagus by the 
string, collecting exfoliated and scraped mucosal cells. In both methods, the collected 
cells are processed and stained for cytology and read for cellular abnormalities.
                                 Among 500,000 Chinese who were screened, this technique had 
90% accuracy in detection of cancer. Among lesions detected, 70% to 80% were early 
lesions13.  
                                  The use of molecular markers is the second noninvasive modality  
that has been used to screen for SCC and its precursor lesions. They can sometimes be 
detected in clinical samples such as blood or stool that can be collected noninvasively. 
Molecular  changes  in  DNA  (e.g.,  hypomethylation,  loss  of  heterozygosity,  and 
mutations) can be amplified by PCR.
                                When screening is performed endoscopically, visual inspection to 
identify pathology is the first step. If chromoendoscopy is to be used, it generally is 
performed before performing biopsies.  In the absence of staining,  dysplastic mucosa 
may appear normal, nodular, white, red, or as an erosion or plaque. Early SCC is usually 
seen as an erosion, a plaque, or a nodule.
                                    Early detection of SCC or dysplastic squamous epithelium may be 
enhanced with vital staining. Diluted Lugol's solution delivered endoscopically through 
a spray catheter has been most  widely used.  Lugol's  solution is rapidly taken up by 
normal  squamous  mucosa,  in  contrast  with  dysplastic  or  malignant  squamous 
epithelium, which remains unstained .  This technique may also be applied to detect the 
extent of mucosal surface involvement when endoscopic therapy is being contemplated 
for  macroscopically  recognized  lesions.  Tissue  sampling  from  the  unstained  areas 
confirms the presence and extent of mucosal involvement.
                         The utility of mucosal iodine staining to improve endoscopic 
visualization of dysplasia and SCC was evaluated in the high-risk population of Linxian, 
China14.  
                         Methylene blue dye staining has been demonstrated to be useful in the 
detection of specialized columnar epithelium, but its accuracy in detecting neoplastic 
changes has not been confirmed consistently15. 
INVESTIGATIONS:
                     Laboratory results may indicate hypoalbuminemia and anemia secondary to 
bleeding  or  chronic  disease.  Hypercalcemia  due  to  bony  metastases  or  circulating 
humoral factors such as parathyroid hormone related peptide in SCC has been reported 
in 15% to 30% of patients16. Hepatic enzymes including alkaline phosphatase and the 
international normalized ratio may be increased in the setting of hepatic metastases.
                          Posteroanterior  and lateral chest radiography is indicated in patients 
with chronic cough and abnormal findings on auscultative examination of the chest to 
demonstrate  pulmonary  metastases  and/or  infiltrates  suggestive  of  aspiration 
pneumonitis or oesophagorespiratory fistula. Findings may also include lateral deviation 
of  the mediastinal  contents,  widening of  the mediastinum,  and oesophageal  air-fluid 
levels.
BARIUM  SWALLOW
                     Barium oesophagraphy remains the study of choice for characterization of 
oesophageal  strictures.  Oesophageal  carcinoma  may  demonstrate  a  variety  of 
appearances on barium oesophagrams. 
• Lesions  may  be  annular  and  constricting;  intraluminal,  polypoid,  or  masslike; 
infiltrative; ulcerating; or varicoid. A mixed pattern is most common.
• A double-contrast technique should be used for optimal sensitivity.
• The length and location of the involved oesophageal segment and the functional 
impairment resulting from the lesion should be reported.
• There  are  ten  segments  in  the  oesophagus -  Marcel Brombert Classification.
                           Contrast radiographic studies should be used to confirm or refute 
suspected osophagorespiratory fistula and complete obstruction. In this context, barium 
is generally the preferred contrast agent, as opposed to diatrizoate meglumine,  which 
may cause pulmonary inflammation or edema if it enters the airway via aspiration or a 
fistula. 
 ENDOSCOPY 
                           Flexible endoscopy is indicated in suspected oesophageal carcinoma.  
Endoscopy allows direct visualization of the oesophagus, as well as tissue sampling, to 
confirm  the  diagnosis.  Endoscopy  allows  accurate  characterization  of  the  tumor's 
configuration, length, and localization. Endoscopy also allows initial relief of dysphagia 
in that dilation can be performed at the time of diagnosis. Standard endoscopic forceps 
biopsy typically yields a diagnosis. Biopsy procedures should be directed at non-necrotic 
areas. At least six biopsy samples should be obtained to yield an accuracy approaching 
100%17.  Occasionally  submucosal  spreading  tumors  require  endoscopic  ultrasound 
(EUS)–guided  fine-needle  aspiration  for  histologic  diagnosis  when  standard  forceps 
biopsies fail. 
CT SCAN
                           Contrast-enhanced CT plays an important role in the staging of 
oesophageal  carcinoma.  Attention  is  directed  in  determining  the  extent  of  the  local 
tumor; invasion of mediastinal structures; involvement of supraclavicular, mediastinal, 
or upper abdominal lymph nodes; and distant metastases. CT examination should extend 
from  the  thoracic  inlet  through  the  liver.  Routine  oral  contrast  material  should  be 
administered. This may be positive contrast agent, such as dilute barium, or a negative 
intraluminal  contrast  medium,  such  as  water.  Techniques  for  virtual  oesophageal 
endoscopy have also been described using effervescent granules and glucagon.
 Key findings include the following:
• Eccentric or circumferential wall thickening is greater than 5 mm.
• Peri-oesophageal soft tissue and fat stranding may be demonstrated.
• A dilated fluid- and debris-filled oesophageal lumen is proximal to an obstructing 
lesion.
• Tracheobronchial  invasion  appears  as  displacement  of  the  airway (usually  the 
trachea or left mainstem bronchus) as a result of mass effect by the oesophageal 
tumor. 
• Aortic invasion may be assessed in 2 ways. 
o The Picus method considers the arc of contact between the tumor and aorta 
(Picus, 1983). Loss of the periaortic fat plane over less than 45° suggests no 
aortic invasion, whereas contact over 90° or more is predictive of invasion 
of the aortic wall. Contact between 45-90° is indeterminate. Accuracy with 
this method is 80%.
o Obliteration of the triangular fat space between the aorta, oesophagus, and 
spine is another predictor of aortic invasion.
                     A short-axis diameter exceeding 1 cm is considered abnormal for lymph 
nodes in all mediastinal locations except those in the subcarinal region, in which 1.4 cm 
is the upper limit of normal. 
                       In a review of 838 patients with M1 disease, Quint et al found that 
metastases were diagnosed most commonly in the abdominal lymph nodes (45%); liver 
(35%);  lung (20%);  cervical  and/or  supraclavicular  lymph nodes  (18%);  bone (9%); 
adrenal glands (5%); peritoneum (2%); brain (2%); or stomach, pancreas, pleura, skin or 
body wall, pericardium, or spleen (1% each). 
                          Its sensitivity for the detection of lymph node metastases is in the range 
of  60-80%.  Its  specificity  is  higher,  approximately  90%.  Lesions  in  solid  organs 
identified  at  CT may represent  primary  benign or  malignant  processes  or  metastatic 
disease, and biopsy is frequently necessary to obtain histologic proof.
MRI
                          MRI presents the advantage of direct multiplanar imaging capabilities,  
which may be of particular use in assessing tracheobronchial, aortic, and pericardial  
invasion. Currently, MRI has not yielded other significant advantages compared with  
CT in the staging of esophageal carcinoma. 
                          Recent research studies suggest that T2-weighted MRIs obtained with 
an endoluminal coil can reveal 7 layers of the  oesophageal wall. In the future, such 
resolution may offer superior assessment of the depth of tumor invasion. Preliminary 
studies have shown that the sensitivity and specificity of MRI for the determination of 
tumor invasion are equivalent to those of CT.
ENDOULTRASOUND
                           Unlike CT, EUS allows visualization of the distinct  5 layers within the 
oesophageal  wall.  Alternating  circumferential  layers  define  the  mucosal  interface 
(hyperechoic), the mucosa (hypoechoic), the submucosa (hyperechoic), the muscularis 
propria  (hypoechoic),  and  the  adventitial  interface  (hyperechoic).  Such  resolution 
permits the distinction of T1, T2, T3, and T4 tumors. Oesophageal carcinoma appears as 
a hypoechoic lesion disrupting the normal circumferential layers. 
                           Local lymph nodes are also demonstrated by using EUS. Nodes are 
considered malignant if they are round, if they are hypoechoic, and if they have well-
defined borders. Usually, benign nodes are hyperechoic and less well defined.
                             T-stage accuracy with EUS is in the range of 79-94%. Accuracy is 
better for T3 or T4 lesions than for T1 or T2 lesions18. Massari et al showed that a 12-
MHz transducer outperforms a 7.5-MHz transducer, with accuracy for T staging of 94% 
and  82%,  respectively.  N-stage  accuracy  is  in  the  range  of  69-90%;  according  to 
Rasanen et  al,  the  technique  probably  outperforms  CT and PET in  the  detection  of 
locoregional lymph node metastasis.
                               EUS-guided fine-needle aspiration  has significantly improved the 
ability to confirm malignant adenopathy. The procedure has been demonstrated to be 
safe and effective for puncturing periesophageal mediastinal nodes,  as well  as celiac 
lymph  nodes19.  The  sensitivity,  specificity,  positive  predictive  value,  and  negative 
predictive value for EUS combined with FNA in the assessment of celiac nodes range 
from 53% to 98%, 77% to 100%, 79% to 100%, and 82% to 100%, respectively20. 
NUCLEAR MEDICINE
                               PET is quickly becoming a standard oncologic imaging modality. 
The technique is useful not only for the primary detection of tumor and metastases but 
also for the further characterization of abnormalities discovered by using other imaging 
modalities. 
                                 2-[Fluorine 18]-fluoro-2-deoxy-D-glucose (FDG) is the most 
commonly used radiopharmaceutical. Radiopharmaceuticals other than FDG can be used 
in  PET  imaging.  Carbon-11  choline  has  received  particular  attention.  Choline,  a 
component of the cell membrane, is taken up by actively dividing cells.11C-choline PET 
scanning  has  been  shown  to  outperform  FDG  PET  scanning  in  the  detection  of 
malignant mediastinal lymph nodes. With this agent,  tumor   containing  mediastinal 
lymph nodes as small as 4  mm have  been identified.The  short half-life of 11C-choline 
(approximately  20  min)  will  likely  limit  its  use  to  major  academic  centers. 
The sensitivity of FDG PET in assessing nodal metastasis is reportedly 33-83%, but 
studies have shown the superiority of FDG PET to CT and EUS for determining the N 
status21. FDG PET is more sensitive than CT for the detection of distant metastases.
TREATMENT
                               Oesophageal cancer is a treatable disease that is rarely curable. The 
overall 5-year survival rate in the subgroup of patients amenable to surgery ranges from 
5% to 20%.    
                                Primary treatment modalities include surgery alone or chemotherapy 
with  radiation  therapy.  Combined  modality  therapy  (chemotherapy  plus  surgery,  or 
chemotherapy  and  radiation  therapy  plus  surgery)  is  under  clinical  evaluation. 
Endoscopic mucosal resection22 and/or photodynamic therapy23 in selected patients with 
superficial  carcinoma  is  also  under  clinical  evaluation.  Effective  palliation  may  be 
obtained  in  individual  cases  with  various  combinations  of  surgery,  chemotherapy, 
radiation therapy, and endoscopic therapy.
PRIMARY THERAPY 
                                 Surgery is the treatment of choice for early (superficial) tumors.  
Once  symptoms  (dysphagia,  in  most  cases)  are  present,  oesophageal  cancers  have 
usually invaded the muscularis propria or beyond and may have metastasized to lymph 
nodes or other organs.
                             Surgical treatment of resectable oesophageal cancers is associated 
with a 3% to 10% operative mortality rate24. Operative morbidity includes anastomotic 
leaks and strictures (20%) and cardiopulmonary complications. One approach advocates 
transhiatal oesophagectomy with anastomosis of the stomach to the cervical esophagus. 
A second approach advocates abdominal mobilization of the stomach and transthoracic 
excision  of  the  oesophagus  with  anastomosis  of  the  stomach  to  the  upper  thoracic 
oesophagus or the cervical oesophagus. Although a transthoracic resection permits better 
visualization of the tumor and a more thorough dissection of adjacent lymphatics, the 
thoracotomy increases the risk of cardiopulmonary complications, and if the transhiatal 
technique is used, places the patient at risk for an anastomotic leak in the chest. The 
result  of  one  study  suggests  that  the  transhiatal  approach  has  a  lower  rate  of 
perioperative (mainly pulmonary) complications25. 
                           As an alternative to surgery, definitive radiation therapy in combination 
with  chemotherapy  has  been  studied.  One  series,  evaluating  radiation  therapy  and 
chemotherapy  with  fluorouracil  and  mitomycin,  produced  a  75% local  control  rate, 
associated with improved swallowing,  and a 30% actuarial  disease-free survival  rate 
(18%  overall  survival)  at  5  years  for  stage  I  and  stage  II  patients26.  An  Eastern 
Cooperative  Oncology  Group  trial  of  135  patients  showed  similar  results,  in  that 
chemotherapy plus radiation yielded a better 2-year survival rate than radiation therapy 
alone27. 
                           The logic of neoadjuvant chemoradiation is appealing. It offers 
potential  early  treatment  for  micrometastatic  disease   and  it  could  assist  surgical 
resection by downstaging cancer. Additionally,  patients seem to tolerate preoperative 
chemoradiation better than postoperative therapy28.
ENDOSCOPIC THERAPY FOR SUPERFICIAL CARCINOMA 
                           Early oesophageal cancers are defined as those confined to the mucosa 
or submucosa, T1N0M0 . In Japan there has been a further division of T1 lesions. T1M 
implies mucosal involvement, and submucosal invasion may be termed  T1SM1 (upper 
third); T1SM2 (middle third); and T1SM3 (lower third). Submucosal invasion (T1SM 1-3) 
carries a 5% to 40% risk of lymph node metastasis29.
                               Superficial oesophageal cancers have been treated endoscopically by 
mucosal resection (EMR), laser therapy, or argon plasma coagulation. Photodynamic 
therapy  (PDT)  also  uses  endoscopy.  Superficial  tumors  have  also  been  treated  with 
radiation  therapy  and  brachytherapy.  The  most  common  technique  employs  a 
transparent suction cup, fitted to one end of the endoscope30. This technique, like most 
others, uses preresection submucosal injection to create a pseudopolyp, which is then 
resected  by  snare  polypectomy.  The  band  ligation  method  is  a  variation  on  this 
technique. Lift and cut methods generally employ a two-channel endoscope31. Recently, 
insulated tipped electrocautery knives have been used to perform resection without the 
need for suction 32. 
                            Five-year cure rates for intramucosal squamous cell carcinomas have 
been as high as 100%, while those that penetrated the submucosa had 5-year survival 
rates of 54% to 59%.Complication rates of 7% were reported in large series and were 
primarily hemorrhage, perforation, and stenosis 33. 
                             Early oesophageal adenocarcinoma and HGD have been treated 
endoscopically in the setting of Barrett's oesophagus. Endoscopic mucosal resection has 
been used alone or in combination with photodynamic therapy or with thermal therapies. 
When the expertise is present and if the pathology can be localized, endoscopic resection 
is increasingly becoming the treatment of choice. 
PALLIATIVE THERAPY 
                            Most patients with oesophageal cancer have advanced disease at the 
time of initial presentation and less than 20% survive 1 year after the time of diagnosis. 
At diagnosis, approximately 50% of patients with oesophageal cancer have metastatic 
disease and are candidates for palliative therapy.
                            Standard palliative treatment options may include radiation therapy, 
chemotherapy,  combination  chemoradiotherapy,  intraluminal  brachy-therapy  and 
endoscopic therapies. All of the preceding modalities may be offered in combination 
with  endoscopic  tumor  dilation,  intubation,  or  ablation.  Chemotherapy  has  yielded 
partial responses among patients with metastatic distal  oesophageal AdenoCA. Many 
chemotherapeutic agents are active in oesophageal cancer. Objective response rates of 
30% to 50% are commonly reported with platinum-based combination regimens with 
fluorouracil, a taxane, or a topoisomerase inhibitor 34.
                          The main goal of endoscopic therapy is palliation of dysphagia, which 
contributes  to  improved  nutritional  status  and  quality  of  life.  Endoscopic  palliative 
therapies can be divided into those methods that displace tissue (dilation, stenting) and 
those  that  ablate  tissue.  Ablative  therapies  destroy  tissue  by  using  contact  thermal, 
noncontact  thermal,  cytotoxic  injection,  and  photodynamic  therapies.  Bleeding  and 
oesophagorespiratory  fistulas  are  other  complications  that  can  be  managed  with 
endoscopic  therapy,  but  symptoms  of  pain  and  anorexia  cannot  be  managed 
endoscopically. Oesophagorespiratory fistulas, which are a dire complication of SCCA 
of  the  oesophagus,  as  well  as  primary  pulmonary  malignancies  that  invade  the 
oesophagus, are particularly well managed with oesophageal stent placement.
DILATION 
                       Dilation achieves tumor displacement by the use of lateral shearing forces 
to stretch and tear the stenotic tissue. Dilation may be performed as primary palliative 
therapy or adjunctively to assist longer-lasting thermal or stent therapy.
                           There are two types of commonly used dilators: polyvinyl dilators 
(Savary-Guilliard or American type) and hydrostatic through-the-scope (TTS) balloons. 
Advantages of dilation include simplicity, low cost, wide availability, short procedure 
time, and relative safety. Most patients derive initial benefit from dilation therapy to a 
luminal diameter that allows passage of a liquid to soft diet (12 mm). However, dilation 
can be complicated by perforation in up to 10% of cases. The main disadvantage of 
dilation  therapy  is  that  its  relief  is  often  short-lived,  and  as  the  disease  progresses, 
symptom-free intervals decrease in duration, requiring more frequent sessions.
CONTACT THERMAL THERAPY 
                       Contact thermal ablation therapies are no longer widely used for palliation 
of dysphagia associated with advanced oesophageal cancer. The electrosurgical tumor 
probe (BICAP tumor probe) is a contact thermal ablation technique used primarily in the 
palliation of circumferential oesophageal malignancies. The assembled apparatus has a 
central lumen that enables the system to be passed over a guidewire. The tumor probe 
produces  a  predictable  depth  of  injury  because  contact  with  nondesiccated  tissue  is 
required to complete the circuit.
                              The procedure is performed under combined endoscopic and  
fluoroscopic  guidance.  In  the recommended retrograde approach,  the tumor probe is 
passed over a guidewire and through the area of luminal narrowing. Under fluoroscopic 
guidance, the probe is then pulled back in retrograde fashion so that the electrosurgical 
component  of  the  tumor  probe  is  in  contact  with  the  malignant  tissue.  The  active 
electrode is 1.5 cm in length, so by withdrawing the tumor probe at 1-cm intervals, a 
small  amount  of  overlap  is  achieved  and  uniform tissue  injury  is  delivered  to  the 
treatment  zone.  At  follow-up  endoscopy  48  hours  postprocedure,  necrotic  debris  is 
removed and additional therapy applied on the basis of clinical results.Technical success 
with increased luminal  diameter  and significant  improvement  in  dysphagia  has been 
consistently  reported for  80% to 90% of  patients35. Generally,  one  or  two treatment 
sessions achieved a mean duration of palliation of 7 to 8 weeks.
ENDOSCOPIC LASER THERAPY 
                         Endoscopic laser therapy  is a noncontact means of thermal ablation. 
Laser photoablation has been used extensively in the palliation of malignant dysphagia 
associated with oesophageal cancers.                               
                          Neodymium:yttrium-aluminum-garnet(Nd:YAG), potassium titanyl 
phosphate  (KTP),  and  argon  lasers  have  been  used  for  thermal  therapy  of  GI 
malignancies. Laser therapy has the capacity to vaporize tissue in addition to producing 
coagulation necrosis.  When feasible,  the retrograde method is  preferred. For annular 
lesions, circumferential treatment should be applied at each level. ELT, in addition to 
tumor  ablation  and  coagulation  necrosis,  often  produces  some  tissue  edema  and 
swelling,  which  may  result  in  transient  luminal  narrowing.  When  complete  luminal 
obstruction is present, ELT in antegrade fashion is necessary.
                              Once the desired extent of luminal patency has been attained, follow-
up endoscopy should be carried out in 3 to 4 weeks to assess the need for repeat ELT 
versus expectant therapy for worsening dysphagia. A contrast barium swallow may be 
considered after completion of ELT to document the effects of therapy. The diet should 
include liquid nutritional supplements. 
                           ELT achieves technical success with luminal patency in 97% of cases, 
whereas functional success defined by relief of dysphagia occurs in 70% to 85%. Sixty 
to seventy percent of patients remain free of dysphagia for 3 to 6 weeks. Only 20% to 
25% of patients treated remain symptom free for 3 months or more  36. Complications 
occurred in 4.1% of cases in a survey of 1359 cases. Perforation occurred in only 2%; 
the procedure-related mortality rate was 1%; the incidence of fistula or hemorrhage was 
1%; and sepsis occurred in 0.5% to 1%. Perforations are more likely to occur in patients 
who have had prior radiation therapy. 
                           Favorable and unfavorable characteristics of endoscopic laser therapy 
have  been  identified.  Characteristics  that  favor  successful  ELT  include  a  mucosal, 
exophytic, or polypoid endoscopic appearance of the tumor. Straight segments are more 
easily treated and have better outcomes than angulated segments. Short tumor segments, 
less than 6 cm, are more effectively treated than more extensive ones. Lesions that occur 
in close proximity to the upper esophageal sphincter are difficult to treat because aiming 
the laser beam is more difficult in this location. Likewise, lesions at the EG junction that 
are horizontal in orientation are more difficult to treat because of difficulty in aiming.
ARGON PLASMA COAGULATION
                      Argon plasma coagulation is emerging as an alternative to laser 
photocoagulation for ablation of superficial luminal digestive tract lesions. Because of 
the limited depth of injury achieved by APC (2 mm), there is limited benefit in treating 
advanced bulky tumors. 
CYTOTOXIC INJECTION THERAPY 
                          Cytotoxic injection therapy is theoretically attractive in that it is cheap, 
simple, and readily available. A variety of chemical agents have been used for palliation 
of  oesophageal  cancers,  both  by  debulking  tumors  and  by  controlling  bleeding  37. 
Injectates  have  included  chemotherapeutic  agents  and  chemical  sclerosants  such  as 
polidocanol,  ethanol,  and sodium morrhuate.  Tissue  destruction  is  brought  about  by 
chemical necrolysis. Disadvantages are the inability to control the depth of tissue injury 
and the lack of immediately visible tissue effects. 
PHOTODYNAMIC THERAPY 
                            The biological effects of photodynamic therapy (PDT) are 
photochemical,  as  cytotoxicity  is  induced  by  nonthermal  laser  light  energy.  A 
photosensitizing agent is administered intravenously and is selectively retained in tumor 
cells.  The  photosensitizing  agent  is  then  activated  by  low-dose,  wavelength-specific 
laser light delivered in close proximity to the lesion. Activation by light produces a local 
cytotoxic  effect  mediated  by  singlet  oxygen.  Two  randomized  comparative  trials 
reported palliation equivalent to that of Nd:YAG laser therapy. PDT for palliation of 
malignant  dysphagia  has  been  reported  using  aminolevulinic  acid,  an  exogenous 
porphyrin precursor, as a photosensitizing agent and nonlaser (high-power xenon lamp) 
light source with encouraging results in a phase II trial. A major advantage of PDT is 
that  large  areas  may  be  treated  during  a  single  session.  Complications  and  adverse 
events associated with PDT include skin photosensitivity, chest pain, atrial fibrillation, 
odynophagia, and stricture formation. 
OESOPHAGEAL STENTS 
                         Expandable metallic oesophageal stents are indicated for the palliation of 
luminal  stenosis  due  to  oesophageal  cancer  and  for  the  management  of 
oesophagorespiratory  fistulas.  Self-expanding  metallic  stents  have  replaced  their 
semirigid plastic predecessors because they are easier to place, achieve more effective 
palliation, and are associated with fewer complications. Covered or coated SEMSs are 
the most effective means of palliating oesophagorespiratory fistula .
                             Accurate tumor length measurement is critical to successful SEMS 
deployment.  Prior  radiographic  contrast  swallowing  studies  may  be  helpful  to 
characterize a tortuous stenosis or an oesophagorespiratory fistula. The type, length, and 
diameter of stent selected are individualized to the specific patient's condition and the 
operator's experience. Dilation is necessary, however, when luminal obstruction does not 
permit the endoscope to pass. 
                           Accurate tumor margin marking is critical to effective stent placement.  
One or more marking techniques may be used. Externally affixed radiopaque markers 
become less useful when the patient moves during delivery device insertion. Simply 
marking the proximal and distal  tumor margins,  as  measured endoscopically,  on the 
delivery device is sufficient in many cases. More precise marking of the tumor margins 
or center point can be achieved by submucosal injection of a radiocontrast agent using a 
sclerotherapy needle or by endoscopic placement of metallic mucosal clips. Familiarity 
with the specific stent delivery apparatus, the significance of its radiopaque markings, 
and the degree of anticipated foreshortening is critical. 
                             Postprocedure, patients who have stents placed across the EG junction 
should have instructions for head-of-bed elevation greater than 30 degrees at all times. 
Antiemetics and antitussives may be used when retching, coughing, or hiccupping is 
significant early on to prevent stent dislodgment. Clear liquids may be initiated on the 
same or  following day and the diet advanced as tolerated.  Dietary recommendations 
should be individualized. Patients are advised to chew food well; avoid stringy meats, 
fruits, and vegetables; flush the oesophagus frequently with liquids during meals.
                            A variety of oesophageal SEMSs are commercially available. They 
are covered  and uncovered  stents.The Wallstent II (Microvasive, Boston Scientific) 
consists of a bilayer chromium alloy tubular mesh coated with a polyurethane sleeve 
between two mesh tubes.  The  Flamingo Wallstent  is  a  popular  modification of  this 
covered stent with an exaggerated proximal flange to reduce occurrences of distal stent 
migration.
                             The Ultraflex stent (Microvasive, Boston Scientific) consists of a 
knitted nitinol wire tube. The stent is constrained on the introducer catheter by a spiral 
retention suture. Unraveling the suture deploys the stent. One unique advantage of this 
stent is that models with distal or proximal release systems can be selected. 
                              The “Z”-stent (Cook Medical) is made of stainless steel wires shaped 
in a Z configuration. It has uncovered segments in the proximal and distal sections that 
have reduced this risk. A model designed with a latex “wind-sock” extending from the 
distal opening of the stent (Dua stent) and intended to prevent gastroesophageal reflux 
has been marketed for EG junction and distal oesophageal cancers for which the stent 
must bridge the EG junction. 
                              The Polyflex (Boston Scientific) is a completely coated self-
expanding nonmetallic (plastic) stent recently introduced and approved by the Food and 
Drug Administration  for palliation of malignant and benign dysphagia. Published series 
have  shown  the  Polyflex  stent  to  be  safe  and  effective  in  relieving  malignant 
dysphagia38. Published  series  have  reported  uniformly  good  results  for  palliation  of 
dysphagia, as well as oesophagorespiratory fistulae.
                               Covered SEMSs were effective in palliating fistulas in 70% to 100% 
of cases. For this complication of oesophageal cancer, SEMSs are uniquely qualified. 
Potential  complications  of  SEMS  placement  include  tumor  ingrowth  or  tumor 
overgrowth  (5%  to  20%),  stent  migration  (10%),  and  chest  pain.  Laser  or  contact 
thermal  therapy  is  effective  for  ablation  of  tumor  overgrowth  of  previously  placed 
stents.  Other  complications  may  include  procedure-related  perforation,  food  bolus 
impaction, bleeding, foreign body sensation, and reflux oesophagitis. Gastrorespiratory 
aspiration is of particular concern among patients in whom the stent crosses the EG 
junction. 
ENTERAL NUTRITION 
                      Most patients with advanced oesophageal cancer have compromised 
nutritional  status.  When feasible,  enteral  is  preferred  to  parenteral  nutrition  support. 
Enteral nutrition support may be indicated in an attempt to improve functional status 
before and after surgery, during chemoradiotherapy, and as an adjunct to other palliative 
measures.
                             Enteral access can be achieved surgically, radiographically, or  
endoscopically.  A  surgical  jejunostomy  should  routinely  be  created  at  the  time  of 
esophageal resection. Percutaneous endoscopic gastrostomy (PEG) is safe and effective 
for  nonoperative  candidates.  PEG  placement  is  not  appropriate  for  candidates  for 
subsequent  oesophagectomy  with  gastric  pull-up.  Direct  gastric  feeding  may  be 
contraindicated  in  patients  with  SEMSs that  extend beyond the  EG junction  and  in 
postesophagectomy patients because of its increased risk of gastrorespiratory reflux and 
aspiration. Poor gastric emptying is observed in many patients who have EG junction 
carcinomas that extend into the gastric cardia and fundus. In these patients, endoscopic 
enteral access can be achieved by creating a direct percutaneous endoscopic jejunostomy 
or a PEG with a jejunal feeding tube extension39.
ANALGESIC THERAPY 
                       Pain due to tumor ulceration and neural invasion is observed in patients 
with advanced oesophageal cancer. Pain may be significant in some patients after stent 
insertion, as a result  of radial expansion. This pain generally lasts for 1 to 2 weeks. 
Oesophageal  cancer  pain  should  be  managed  with  narcotic  analgesia.  Long-acting 
sustained  release  preparations  may  be  supplemented  with  shorter-acting  agents. 
Parenteral  applications  such  as  transdermal  patches  have  obvious  appeal  for  use  in 
patients with dysphagia.
PRIMARY  PREVENTION
                                  According to the  World  Cancer  Research  Fund,  50% to  70%  
of  SCC  could  be  avoided  by  implementation  of  guidelines  for  a  healthy  lifestyle.  
There   is  some   evidence   that   anti-inflammatory   medication  may   prevent  
deterioration  to  cancer  in  intestinal  metaplasia.
SECONDARY PREVENTION
                               It  is  aimed  at  detecting  neoplasia  at  a  curable  stage  in  
asymptomatic  persons. High  resolution  endoscopy  is  useful  in  identifying  early  
lesions. In  western  countries,  endoscopic  screening is  recommended  in   persons 
with  high  consumption  of   alcohol  and  tobacco.  Screening  is   justified  after  
treatment   for  head  and  neck  cancer. Factors  justifying  surveillance  are  male  sex,  
a  prolonged  symptomatic  history  of  GERD,  continuous  smoking  and  presence  of  
peptic  stricture  or  ulcer  in  intestinal  metaplasia  cases.
                                           AIM   OF  THE  STUDY
1. To  study  about  the  demographic   features  of  carcinoma  oesophagus.
2. To  assess  the influence of    risk factors   in  the  causation  of  carcinoma 
oesophagus.
3. To  study  the  clinical  features  of  carcinoma  oesophagus and to  correlate  the 
level  of  hold up  of  food  with  the  site  of  lesion.
4. To   assess   the   incidence   of   operability   of   tumour   at   the   time   of 
presentation.
5. To  study  about  the  various  modalities  of  treatment  available  for  these 
patients and  to  assess  the  symptomatic  improvement  after  treatment.
MATERIALS  AND METHODS
                           Patients  included   in  the  study  were  recruited  from  the  
department  of  digestive  health  and  diseases,  Government  Peripheral  hospital,  
Anna Nagar, Chennai. The  study  period  was  from  September  2005  to  March 2008.
                          Consequetive  patients  diagnosed  to  have  carcinoma  oesophagus  
formed  the study  group. Healthy  individuals  who  were  accompanying  the  patients 
formed  the  control   group.The  control   group  individuals  were  matched  with 
patients  for  age (± 5 years)  and  sex.
                        A detailed  proforma  was  completed  for  both the patients  and  
controls. A  detailed  history  about   dietary  habits  and  social  habits  such  as  
smoking,   alcohol,   tobacco   chewing   were   recorded.  Clinical   history   about  
dysphagia,  site  of  hold  up,  anorexia  and  weight  loss  was  obtained and thourough  
clinical  examination was   done. Body mass index was calculated for all.
                         Investigations included haemoglobin, erythrocyte sedimentation rate,  
barium  swallow, U G I Scopy   &   biopsy  and  CTSCAN of the  chest  & upper  
abdomen were  done. In   those  cases  where  scope  cannot  be  negotiated  beyond  the  
growth,  dilatation  was  done  and  extent  detected. Histopathological  grading  was  
done  by  the  pathologist. Treatment  was   individualized  according  to  the  stage  of  
the  disease  at  presentation. Follow  up  of  the  patients  was  done.   
                           The  statistical  analysis  was  done  using  EPI INFO 6. Odds  ratio  
estimates   of   relative   risk   was  calculated for the risk  factors.  Univariate   and 
multivariate  analysis  were  done. P value  of < 0.05  was  found  to  be  significant.  
Percentage  calculation  was  done  whenever  appropriate.
                   
                          
                             
RESULTS
                             The  total  number  of  cases  and  controls  were 155  each. The  male  
female  ratio was  1.67: 1.
                               The  incidence  of  cancer  oesophagus  was  7.1% in  patients  
below  the  age  of  40  years. It  slowly  increased  and  reached the  maximum  in  5th 
decade  and  then  slowly  declining. The  incidence   was  12.9%  in  patients  above  
the  age  of  70.
                               Most  of  them  were  from  places  in  & around Chennai (66.4%).  
Similar  distribution  was  seen  in  controls  also. Most  of  them  did  some  manual  







AGE (mean) Years 58.3 58.3
AGE DISTRIBUTION
< 30 2 (1.3%) 2(1.3%)
31-40 9 (5.8%) 7(4.5%)
41-50 31(20%) 25(16.9%)
51-60 55(35.5%) 52(33.5%)
61-70 38 (24.5%) 42(27.1%)
> 70 20(12.9%) 27(17.4%)
RESIDENCE
Chennai 87 (56.1%) 83(53.6%)
Coimbatore 1(0.7%) 3(1.9%)
Salem & Erode 27(17.4%) 23(14.8%)


















                                         
About  49%  of  patients  were  illerate  whereas  only  38%   of  controls  were  illerate.  
Majority  of  the  patients  and  controls  belonged  to  hindu  religion ( 89%  and  92%).  
There   were  no  muslims  in  control   group  but  6.5%  of  the  patients  belong  to  
muslims.
RISK  FACTORS
                               No one in  the  control  &  case  group  had  history  of  corrosive  
intake  or  achalasia cardia. One  patient  in  case group  and  3  in  control  group  had  
history  of  gastric  surgery. 4  patients  had  past  history  of  head &  neck  malignancy 
and  radiotherapy. None  in  the  control  group  had  malignancy   or  radiotherapy. 7  
patients   had  postcricoid  web  prior  to   or   during  the  diagnosis   of   cancer  
oesophagus.











































Tea / Coffee 
> 2 cups/day 







Yes 33(21.3%) 74(47.7%) 0.42
No 122(78.7%) 81(52.3%)
0.22-0.81 0.01
             About  43% &  51%  of  cases  used  alcohol  and   smoking  respectively,  
whereas  only  19%  &   17% used   alcohol  and  smoking  in  the  control  group. On  
doing  univariate  analysis  the  risk  of  oesophageal  cancer  was  found  to be  1.7  
times  higher  with  alcohol  consumption, 1.16  times  higher  with  smoking,  4.63  
times higher  with  tobacco,  4.14  times  higher  in  patients  with  family  history  of  
cancer,  11.53  times  higher  with  tea &  coffee  > 2  cups per  day and 0.42  times  less  
common  in  patients  who  took  green  vegetables  &  fruits  daily.
                              On  doing  multivariate  analysis,  only  tobacco  consumption,  tea  
&  coffee  intake> 2 cups/day  & not taking  vegetables  and  fruits  daily  were  found  









GI Bleed 3(1.9%) 152(98.1%)
Reduced Appetite 39(25.2%) 116(74.8%)
Weight Loss 134(86.5%) 21(13.5%)
DYSPHAGIA SCORE 1 2 3 4
10(6.5%) 24(15.5%) 100(64.5%) 20(12.9%)
DURATION(DAYS) <15 15-30 30-90 >90
18(11.6%) 43(27.7%) 62(40%) 31(20%)
SITE OF HOLD UP THROAT UPPER CHEST MID CHEST LOW CHEST
90(58.1%) 22(14.2%) 36(23.2%) 7(4.5%)
        
                          Dysphagia  was  present  in 98.4%  of  patients. Majority of  the 
patients(64.5%)  had  grade  3  dysphagia according  to  Atkinson et  al  score. About  
40% of  patients  had  dysphagia  for  30-90 days.11.6%  had  short  duration (15 days)  
of  dysphagia. Site of  hold up was in the throat in 58.1%& in midchest in 23.2% of  
patients.  Odynophagia   was  seen  in  18.7%,  heartburns   in  4.5%,  regurgitation   in  
40.6% of   cases.Aspiration in   43.2%,  vomiting in  41.9% ,  GI  bleed in  1.9% were  
recorded. 25.2% had  reduced  appetite  and   86.5%  had  weight  loss.
CLINICAL FINDINGS
                          The  body  mass  index  was  between  16- 20 in  84.5% and  it  was  <  
15 in 4.5% where as only  11.1% had  BMI in  between  21-25. Pallor   was  present  in  
94.8% of  patients. Only  12  cases  had  lymph node enlargement. None  had  either  
tylosis  or  acanthosis nigricans. 16  cases  had  aspiration  pneumonitis. 10  cases  had  
hepatomegaly  with  secondaries.CVS & CNS  were  normal  in  all  cases.




LYMPH NODE 12(7.7%) 143(92.3%)
TYLOSIS 0 155(100%)
ACANTHOSIS NIGRICANS 0 155(100%)
NORMAL ABNORMAL
RESPIRATORY SYSTEM 139(89.7%) 16(10.3%)
CARDIO VASCULAR SYSTEM 155(100%) 0
ABDOMEN 145(93.5%) 10(6.5%)
CENTRAL NERVOUS SYSTEM 155(100%) 0
INVESTIGATION
                             Haemoglobin  was  low  in 86.5% of  case and  96.1% had  raised  
ESR.  Barium  study   was   done  in   140  cases,  of   which   40%  had  irregular  
narrowing, 34.2% had irregular  narrowing  with shouldering. Tracheo-oesophageal 
fistula was seen  in  6  cases. Typical  rat  tail  appearance  was  seen  in  10.3%  of  
cases.






IRR NAR(1) RAT 
TAIL(2)
SHOULD(3) TOF(4) NOT AVAIL(5) 1,4 1,3 2,4
62(40%) 16(10.3%) 1(0.7%) 0 15(9.7%) 6(3.9%) 53(34.2%) 2(1.3%)
UGI SCOPY
SITE CER ESO(1) UPP 
THO(2)
MID ESO(3) LOW 
ESO(4)
1,2 2,3 3,4 2,3,4
1(0.7%) 11(7.1%) 32(20.7%) 40(25.8%) 10(6.5%) 21(13.5%) 36(23.2%) 4(2.6%)
LENGTH <2 3-5 6-8 >9
6(3.9%) 52(33.5%) 56(36.1%) 41(26.5%)
TYPE ULCER PROLIF U P POLYP
35(22.6%) 65(41.9%) 49(31.6%) 6(3.9%)
EXTENT CIRCUM ECCEN
123(79.4%) 32(20.7%)
T O F Yes No
11(7.1%) 144(92.9%)
HISTOLOGY




A D C  (7.1%) 0 9(81.8%) 2(18.2%)
OTHERS 4(2.6%)
CT SCAN NARROW NAR, 
AOR





1(.7%) 1(.7%) 3(1.9%) 7(4.5%) 3(1.9%)
                                             
                                               U G I Scopy  was  done  for  all  cases. It showed  lesion  in  cervical 
oesophagus in 0.7%, upper  thoracic oesophagus  in  7.1%, mid thoracic oesophagus  in 
20.7%  and  lower   oesophagus   in  25.8%  of  cases.  Lesions  involving  2  segments 
constituted  45.8%, among  which  23.2% of  cases had  growth  involving  both mid & 
lower  thoracic  oesophagus. About  36.1%  had growth of  6-8 cms in length, 26.5% had 
growth of  more  than  9 cms, where as  only  3.9% had growth of < 2cms. 41.9%  had 
proliferative type of growth, 22.6% and 31.6% had  ulcerative and  ulceroproliferative 
growth  respectively.3.9% had polypoidal  lesion. 79.4%  had circumferential  growth 
and 20.6% had eccentric  lesion. Tracheo-oesophageal fistula was  documented  in 11 
cases. 
                             Histopathological  examination  showed  squamous  cell carcinoma  
in  90.3% , adenocarcinoma in 7.1% and  other  types  in 2.6%  of cases. CTScan  
showed  narrowing  alone in 27.7%  and  narrowing  with  aortic involvement in 62.6%. 
Approximately 36.8% were  subjected to  radiotherapy  and  surgery was  done  in 8  
cases.  11 cases had SEMS  stent  deployed for  palliation. Chemoradiotherapy  was 
done  for 25.8%  of cases. 2 cases had  nasogastric tube  placement  alone.
TREATMENT NUMBER OF PATIENTS
SURGERY 8 (5.2%)
SEMS STENT 4 (2.6%)
CHEMOTHERAPY 4 (2.6%)
RADIOTHERAPY 57 (36.8%)
DILATATION / SURGERY 1 (0.7%)
DILATATION / RADIOTHERAPY 24 (15.5%)
RADIOCHEMOTHERAPY 40 (25.8%)
RADIOTHERAPY / STENTING 2 (1.3%)
CHEMOTHERAPY / OTHERS 2 (1.3%)
CHEMO/ STENT/DILATATION 1 (0.7%)
CHEMO/ DILATATION 6 (3.9%)
STENT/ DILATATION 4 (2.6%)
OTHERS 2 (1.3%)
                         Follow  up  was  not available  for 7 cases. 20  cases  had  lost  follow up 
in  between  the  study. Mean  duration  of  follow  up  was  123.1 days( ranging from 15 
to 965days). 
FOLLOW  UP AVAILABLE N  A
148 (95.5%) 7 (4.5%)
POST TRT DYS SCORE 0 1 2 3
3 (2%) 117 
(79%)
16 (10.8%) 12 
(8.1%)
DURATION (MEAN IN DAYS) 156.4
POST RT STRICTURE YES NO
19(15.4%) 104(84.5%)
ANAST STRICTURE YES NO
3(33.3%) 6(66.6%)
                        Post radiation stricture was  seen  in  15.4% of  cases and 33.3% 
developed  anastamotic stricture. On follow up, 2  patients had recurrence,  one  patient  
developed  malignancy  in  stomach ( SCC) and  one  developed tumour overgrowth 
with   occlusion  of  stent.  One patient   developed  non  neoplastic   nodular  lesion  in 
stomach.
                                                  
                                              
DISCUSSION
                             The mean age of carcinoma oesophagus in this study was 58.3 years.  
Schlansky  et al in his report stated  that  the age at initial presentation was 66 years  
which was  similar to this present study40.  The male female ratio in this  study was 
1.67:1,similar  to that quoted  by R.K. Tandon et al41. The mean age of occurrence for 
cancer   oesophagus was  52  years  and male  female  ratio  was 1.5:1,  according   to  
Khuroo et al  2.  Parkin et al report a low prevalence of 7.6/100 000 of oesophageal  
cancer in the age group of 35-39, with an increasing incidence above  the age of 45 42. A 
similar trend was seen in  this study also.Tandon et al showed increased incidence in 4th  
and 5th decade in his study  41. Male preponderance was noted all over the world with 
low sex ratio in India. This may be due to high prevalence of betal nut and tobacco quid 
chewing among the Indian females.
                       28% of the cases were illiterate and 32% received only primary school  
education according to Tandon et al 41. But in this study, 49% & 38% were illiterate in  
cases  and controls respectively. In the present study, oesophageal cancer was more 
common  among  the  hindus,  followed  by  muslims  and  then  Christians.The  Mumbai  
cancer  registry  had  reported  a  preponderance  among  hindus  &  muslims  with  low 
incidence  among       Christians43.  Khuroo  et  al  in  his  study  showed  significant  
differences in hindus, muslims and sikh population. Sikhs had highest incidence in his  
study  2.   In  this  study,  47%  involved  in  unskilled  occupation  and  31.6%  were  
housewives.  But  Tandon  et  al  showed  that  only  21.4% were  involved  in  unskilled 
occupation41. 
                         In western countries, a casual relationship has been established with the  
consumption  of  alcohol  and  tobacco.  Tobacco  was  found  to  interact  with  light  to 
moderate  consumption  of  alcohol  (0.1-30  gms/day)  as  a  risk  factor44.According  to 
Malken et al, 85% of oesophageal cancer was attributed to alcohol and tobacco use in  
U SA & Europe  6. The influence of alcohol is probably related to quality of alcohol  
consumed rather than type or concentration. In Tandon et al study, the relative risk was 
1.85 times higher with alcohol  which was similar to this study. Smoking and tobacco 
chewing increased the risk by 1.16 and 4.63 times in this study, when compared to 2.38 
and 2.36 times in Tandon et al study41. Case controlled studies carried in India revealed 
alcohol  drinking to  be positively  attributed  with oesophageal  cancer45.  Alcohol  may 
contain carcinogenic chemicals and other contaminants that are known or suspected  
carcinogens.  These  include  N-nitroso  compounds,  mycotoxin,  urethane,  tannins,  
inorganic arsenic and other pesticide  residues and asbestoes filtration products that 
may  influence  the  carcinogenic  process46.Nandakumar  et  al  also  showed  increased 
risk(1.95) with smoking 47.
                                Sanghivi et al reported a relative risk of 1.5 – 3.5 for cancer  
oesophagus from betal quid chewing48. Smoking in association  with betal quid chewing 
and alcohol consumption has a multiplicative risk. The combined  use also appears to 
influence the site of cancer oesophagus49.
                                Tandon et al reported a protective role of vegetables and fruits 7.  
Similar results were observed from a study from Mumbai. Notani et al found a risk of  
2.62 times with decreased vegetables intake  50.  In this study, the risk was 0.42 times 
lower in cases who took daily  vegetables and fruits.  The increased risk  due to low 
consumption of green vegetables may be due to absence of anticarcinogenic agents like  
vitamin  A,  C,  selenium,  folic  acid,  dietary  fibre  and  other  plant  sterols.  These 
anticarcinogens bind to carcinogens in the lumen.
                              Khuroo et al had shown that salted tea consumption among  
Kashmiris was responsible for high incidence of cancer oesophagus2.  This has been 
attributed to the high content of nitrosamines. The dietary pattern in India varies in  
different  parts.  Increased risk  has  been reported  with  smoked and fermented  items.  
Thermal trauma when drinking hot beverages > 700 C may play a role in Asia and 
South America44.In this study, taking tea & coffee >2 cups / day increased the risk by 
11.53 times.
                        Family history of cancer increased the risk by 4.14 times in this study.  
Post cricoid web  was seen in  7 cases and head and neck  malignancy and radiation  
were  seen  in  4  cases  each.  All  were  directly   related  to  development  of  cancer  
oesophagus. Only one case in the patient group had undergone gastric surgery whereas  
3  had  undergone surgery in control group. So this was not found to be significant.
                          Dysphagia was the predominant symptom (98.4%) in this study  which 
was similar  to  the  other  studies.  According  to  Schlansky  et  al,  55%  of  cases  had 
dysphagia, 38%  had odynophagia and 15% had weight loss. Less commonly patients 
reported in descending order of frequency, emesis, GI bleed, mass abdomen, anaemia,  
cough, fatigue, anorexia & hoarseness40. According to Dr.Richard Schatzke  in 1958 ,  
involvement  of  about  half  the  circumference  is  required  to  produce  dysphagia  8.  
Odynophagia was present in 18.7%, GI bleed in 1.9%,weight loss in 86.5%of the cases  
in this study. Most of the patients had grade 3 dysphagia and  site of hold up was in the  
throat  in 58.1% of cases  whereas  only  7.2% of cases had growth in  cervical and 
upper thoracic oesophagus. 59% of cases  had  gradeII dysphagia according to Berquist  
et al51. 84.5% of the cases had BMI of between  16 to20  which indicated their  poor  
nutritional status. Pallor was present in 94.8% of  cases and 7.7% of cases had  cervical  
lymph node enlargment.  6.5% had  secondries liver at the time of presentation.    
                           Haemoglobin was low in 86.5%  and increased ESR was found in  
90.1% of cases. Barium swallow revealed  irregular narrowing alone  in 40% of cases,  
narrowing with shouldering (corner sign)  in 34.2% of cases  and rat tail appearance in  
10.3%.  Wion and Felson  described  3 types of roentgenographic  configuration of  
cancer of oesophagus – infiltrative,  polypoid,   and  ulcerative.  The infiltrative form 
present with narrowing in concentric manner. Shouldering  is called as corner sign.  
Lymphoma usually  present as polypoidal lesion. 
                              In this study, endoscopy showed growth in lower oesophagus in  
25.8%,  mid  oesophagus  in  20.7%,  involving  both  middle  and  lower  oesophagus  in  
23.2% &  upper and mid thoracic oesophagus in 13.5%.Berquist et al showed growth in 
distal oesophagus  in 76%, mid oesophagus in 18% and proximal oesophagus in 5% 
similar to this study51.  Cancer oesophagus occurred in upper third in 1.8%,  middle  
third in 60.4% and lower third in 37.8%in Khuroo et al’ s study, which was different  
from  this  study2.  Schalansky  et  al  showed  59% in  mid  oesophagus,  18% in  lower  
thoracic oesophagus  and 23% in upper oesophagus for squamous cell carcinoma and 
97%  in  lower  thoracic  oesophagus  and  3%  in  mid  thoracic  oesophagus  for  
adenocarcinoma40.  The  length  of  the  tumour   was   mostly  ranged  from  6-8cms  in  
36.1%of cases and > 9cms in 26.5%.
                                      Earliest manifestation – hold up in neck  can be misleading 
indication of focus of disease. Length is the most common characteristic in determining  
localized or advanced state. The most frequently published dimension of an early cancer 
is < 5cms length, if the length is < 5 cms, 50% develop nodal metastasis; if it is > 5 cms 
90% develop  nodal  metastasis8.Tracheo-  oesophageal  fistula   was  present  in  7.1%.  
79.4% had circumferential growth and only 20.7% had eccentric growth.
                                   In this study, 90.3% had squamous cell carcinoma, 7.1% had  
adenocarcinoma and 2.6% had other varieties such as small cell and baso squamous  
cell carcinoma. R.Lambert and Hainaut reported that SCC is the most common type and 
ADC is relatively rare. In many countries in Europe and Asia, the proportion of ADC is  
< 10%; higher figures are only shown in the Caucasian population in USA, Australia  
and northen Europe52. Khuroo et al showed  SCC in 85.3%,  ADC in 14.6% of the cases  
and leiomyosarcoma in 2 cases2.Small  cell carcinoma of esophagus was reported by  
Deshpande  et  al  in  199653.  CTScan  showed  liver  secondaries  in  13.4%,  lung 
secondaries in 3.3%. Aortic involvement was noted in 75.4% of cases which precluded 
surgery in these patients.Vyas et al reported 57% of cancer are localized, 14% had  
distant metastasis and another 14% had continuous extension54.
                              Berquist et al’s  study  showed stenting in 67% and brachytherapy  in  
25%  of  cases,  since  he  studied  patients  with  advanced  disease  51.Combined 
chemoradiation  improve  the  prognosis  of  patients  suffering  from  advanced  cancer 
oesophagus.The response rate was 64%  with 25%  complete response55. Van de schoot  
proposed that new  paclitaxel based  neoadjuvant chemotherapy followed by  surgery in  
cases  with  stage  2  or  3  disease  would   be  very   useful56.  The  metaanalysis  which 
analysed 1116 patients altogether concluded that  compared with alone,  neoadjuvant  
therapy improved 3 year survival and decreased local and regional recurrence. Homs 
et al studied 200 patients with SEMS placement for malignant dysphagia, 52 of whom 
had previously received chemotherapy( n=35), radiotherapy (n=8) or both(n=6).  The 
dysphagia score improved in all patients from a median of 3 to 0 at 4 weeks57. In this  
study, only 8 patients underwent surgery, 11 underwent SEMS placement and sizable  
number  of  patients  underwent  radiotherapy  alone  or  along  with  chemotherapy.  
According to Jeevan kumar et al, all the 69 patients who underwent stenting ( choos  
stent) showed improvement in the dysphagia score58.
                          Follow up showed improvement of dysphagia from 3 to 1 in 79% and  3  
to  0  in  2%.   Still  8% had grade  3 dysphagia – may be  related to  post  radiation /  
anastamotic   stricture, recurrence or dysmotility. Post radiation stricture developed in 
15.4% and anastamotic stricture in 33.3% of cases.
 
                            
CONCLUSION
• Oesophageal  carcinoma  is  one  of  the  commonest  digestive  tract  cancer  in  
Chennai.The etiopathogenisis seems to be multifactorial in origin.
• There  are  more  number  of  female  cases  probably  due  to  increased   tobacco  
chewing and illiteracy.
• Smoking and alcohol  intake  increases  the  risk  significantly  and low intake  of 
vegetables aud fruits also is detrimental.
• Dysphagia is present in almost all patients.
• There is no correlation between the site of lesion and site of hold up  of food.
• Delayed presentation precluded curative surgical treatment in most of the cases.
• Many  treatment  modalities  are  available  for  these  cases-  surgery,  
radiotherapy(curative  &  palliative),chemotherapy,  chemoradiotherapy  and 
endotherapy. Multimodal treatment seems to offer good results.
• Symptomatic improvement occurs in 75% of cases.
• Reducing  tobacco  usage  and  dietary  improvement  are  complimentary,  
inexpensive and a practical way to control cancer oesophagus in India. 
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    PROFORMA
NAME:                                                                                                      DDHD  NO:
AGE:                  YRS                                                                               IP  NO:
SEX: MALE / FEMALE                                                                         V OGD  NO:
RESIDENT  OF ( > 5 YRS ):                                                                   ADDRESS:
OCCUPATION: 
SYMPTOMS                                                                                            DURATION
DYSPHAGIA  FOR                            DYSPHAGIA  SCORE:
               
          SOLIDS:
          LIQUIDS:







SITE  OF  HOLD  UP:  (SPECIFY  FROM  MANUBRIUM  STERNI  IN CMS)
REDUCED   APPETITE:
WEIGHT  LOSS:
HISTORY  OF  CORROSIVE  INTAKE:
 
ACHALASIA:
HISTORY  OF   GASTRIC  SURGERY:
HISTORY  OF  RADIATION:
HISTORY  OF  HEAD  &  NECK  MALIGNANCY:
P V  SYNDROME:
CONTACT    WITH    CHEMICALS / FERTILISERS: YES / NO
ALCOHOL: BRAND        :
                     QUANTITY  :                                                          DURATION :
SMOKING: BRAND        :
                      
                     QUANTITY  :                                                             DURATION :
TOBACCO : 
                      
                     CHEW:   DURATION:                                               FREQ / DAY
STUDIED  UPTO                          :
lxx
FAMILY  HISTORY  OF  CARCINOMA : (SPECIFY) 
RELIGION : HINDU / MUSLIM / CHRISTIAN /OTHERS 
DIET  DETAILS:
           VEG /FRUITS  DAILY    YES/ NO
DRINKS:                                     NO.  OF  CUPS / DAY         (200ML / CUP )
              COFFEE                      : 
              TEA                             :
ON   EXAMINATION :
 HEIGHT :             CMS             WEIGHT :            KGS          BMI :
PALLOR :
LYMPH  NODE : YES /NO
TYLOSIS :   YES / NO 
ACANTHOSIS  NIGRICANS :   YES / NO
RESPIRATORY  SYSTEM : CLEAR / CREPS
 
CARDIO VASCULAR   SYSTEM : NORMAL / ABNORMAL
ABDOMEN :   MASS  EPIGASTRIUM  YES / NO
                         LIVER   SIZE
     
                                        SURFACE
                                        BRUIT / RUB
CENTRAL  NERVOUS  SYSTEM :
                        METASTATIC  SYMPTOM / SIGNS
INVESTIGATIONS :
                           HB %
                           ESR                          MMS
                           BARIUM    SWALLOW:
                                           IRREGULAR    NARROWING
                                           RAT  TAIL   APPEARANCE
                                           SHOULDERING
                                           TOF
                           UPPER  GASTRO  INTESTINAL  ENDOSCOPY:
                                           SITE   OF  GROWTH
                                           LENGTH  OF   GROWTH
                                           ULCERATIVE  /   PROLIFERATIVE /  POLYPOIDAL
lxxi
                                           CIRCUMFERENTIAL /  ECCENTRIC
                                           TOF
                         HISTOLOGY: 
                                          SQUAMOUS  CELL  CARCINOMA 
                                                     WELL    DIFFERENTIATED
                                                     MODERATELY  DIFFERENTIATED
                                                     POORLY    DIFFERENTIATED
                                          ADENO CARCINOMA
                                                     WELL    DIFFERENTIATED
                                                     MODERATELY    DIFFERENTIATED
                                                     POORLY    DIFFERENTIATED
                                          OTHERS
                      CT  SCAN   CHEST  &  UPPER  ABDOMEN:
                
                                         NARROWING
                                         AORTA    INFILTRATION
                                         LUNG   SECONDARIES
                                         LIVER    SECONDARIES
                      TREATMENT:
                                      SURGERY: ( IF  OPERABLE)
                                      IF  INOPERABLE - - 
                                                 RADIOTHERAPY
                                                 CHEMOTHERAPY
                                                 SELF  EXPANDING  METALLIC  STENT
                                                 DILATATION
                       FOLLOW  UP:
                                        POST  TREATMENT   DYSPHAGIA  SCORE:
                                        FOLLOW  UP  PERIOD:
                                        POST  RT  STRICTURE :  YES / NO
                                        ANASTOMOTIC   STRICTURE :   YES / NO
                                             
                               
lxxii
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